Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $19.1 million.

  • Syndax Pharmaceuticals' Change in Accured Expenses fell 94.76% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 87.68%. This contributed to the annual value of $19.1 million for FY2024, which is 28.73% up from last year.
  • As of FY2024, Syndax Pharmaceuticals' Change in Accured Expenses stood at $19.1 million, which was up 28.73% from $14.9 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Change in Accured Expenses ranged from a high of $19.1 million in FY2024 and a low of $567,000 during FY2020.
  • In the last 3 years, Syndax Pharmaceuticals' Change in Accured Expenses had a median value of $14.9 million in 2023 and averaged $14.5 million.
  • Data for Syndax Pharmaceuticals' Change in Accured Expenses shows a peak YoY skyrocketed of 388.36% (in 2021) over the last 5 years.
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $567,000 in 2020, then skyrocketed by 388.36% to $2.8 million in 2021, then spiked by 240.23% to $9.4 million in 2022, then spiked by 57.81% to $14.9 million in 2023, then grew by 28.73% to $19.1 million in 2024.